{"id":"NCT03897088","sponsor":"Sun Pharmaceutical Industries Limited","briefTitle":"Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis","officialTitle":"A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-29","primaryCompletion":"2022-02-17","completion":"2022-02-17","firstPosted":"2019-04-01","resultsPosted":"2023-05-31","lastUpdate":"2023-05-31"},"enrollment":231,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Scalp Psoriasis"],"interventions":[{"type":"DRUG","name":"PART 1: Double-blind Placebo-controlled","otherNames":[]},{"type":"DRUG","name":"PART 2: Double-blind Active Treatment Extension","otherNames":[]}],"arms":[{"label":"Tildrakizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"PART 3: Observational Safety Follow-up","type":"NO_INTERVENTION"}],"summary":"This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.","primaryOutcome":{"measure":"The Proportion of Subjects With Investigator Global Assessment Mod 2011 (Scalp) Score of \"Clear\" and \"Almost Clear\" With at Least 2-point Reduction From Baseline at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo Comparator: Placebo","deltaMin":0.073,"sd":null},{"arm":"Tildrakizumab","deltaMin":0.494,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.00001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["United States","Australia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":114},"commonTop":["Nasopharyngitis","Headache","Hypertension","Covid-19","Upper Respiratory Tract Infection"]}}